[pubmed] Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthe

Verrouillé
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 2983
Enregistré le : 31 mai 2020 09:57
3
Zodiaque :
Âge : 20
Contact :
    unknown unknown

[pubmed] Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthe

Message par RSS-Bot »


Clin Exp Immunol. 2020 Jul 24. doi: 10.1111/cei.13499. Online ahead of print.

ABSTRACT

Myasthenia gravis (MG) is an autoantibody-mediated inflammatory disease of the neuromuscular junction. Biomarkers indicating disease activity in MG are warranted. Recently, soluble urokinase plasminogen activator receptor (suPAR) has been reported to be associated with inflammation, tissue damage, disease activity, and prognosis in various diseases, including autoimmune diseases. In this study, serum suPAR levels were measured in 40 patients with anti-acetylcholine receptor antibody-positive MG and in 30 controls, and their correlations with clinical variables and severity scale scores were investigated. We identified that serum suPAR levels significantly correlated with MG activities of daily living scale (Spearman's ρ = 0.45; P = 0.004) and MG Foundation of America classification (Spearman's ρ = 0.37; P = 0.02) at serum sampling, but not with anti-acetylcholine receptor antibody titers. In conclusion, serum suPAR levels can be a candidate for a novel biomarker of disease activity in anti-acetylcholine receptor antibody-positive MG.

PMID:32706905 | DOI:10.1111/cei.13499


Source: https://pubmed.ncbi.nlm.nih.gov/3270690 ... 9&v=2.11.3
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com


Bonne lecture...
Verrouillé

Retourner vers « Echos de la recherche »